Pruis Ilanah J, Koene Stephan R, van der Voort Sebastian R, Incekara Fatih, Vincent Arnaud J P E, van den Bent Martin J, Lycklama À Nijeholt Geert J, Nandoe Tewarie Rishi D S, Veldhuijzen van Zanten Sophie E M, Smits Marion
Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands.
Neurooncol Adv. 2022 Feb 21;4(1):vdac023. doi: 10.1093/noajnl/vdac023. eCollection 2022 Jan-Dec.
Nonenhancing glioma typically have a favorable outcome, but approximately 19-44% have a highly aggressive course due to a glioblastoma genetic profile. The aim of this retrospective study is to use physiological MRI parameters of both perfusion and diffusion to distinguish the molecular profiles of glioma without enhancement at presentation.
Ninety-nine patients with nonenhancing glioma were included, in whom molecular status (including 1p/19q codeletion status and IDH mutation) and preoperative MRI (T2w/FLAIR, dynamic susceptibility-weighted, and diffusion-weighted imaging) were available. Tumors were segmented semiautomatically using ITK-SNAP to derive whole tumor histograms of relative Cerebral Blood Volume (rCBV) and Apparent Diffusion Coefficient (ADC). Tumors were divided into three clinically relevant molecular profiles: IDH mutation (IDHmt) with ( = 40) or without ( = 41) 1p/19q codeletion, and ( = 18) IDH-wildtype (IDHwt). ANOVA, Kruskal-Wallis, and Chi-Square analyses were performed using SPSS.
rCBV (mean, median, 75 and 85 percentile) and ADC (mean, median, 15 and 25 percentile) showed significant differences across molecular profiles ( < .01). Posthoc analyses revealed that IDHwt and IDHmt 1p/19q codeleted tumors showed significantly higher rCBV compared to IDHmt 1p/19q intact tumors: mean rCBV (mean, SD) 1.46 (0.59) and 1.35 (0.39) versus 1.08 (0.31), < .05. Also, IDHwt tumors showed significantly lower ADC compared to IDHmt 1p/19q codeleted and IDHmt 1p/19q intact tumors: mean ADC (mean, SD) 1.13 (0.23) versus 1.27 (0.15) and 1.45 (0.20), < .001).
A combination of low ADC and high rCBV, reflecting high cellularity and high perfusion respectively, separates IDHwt from in particular IDHmt 1p/19q intact glioma.
无强化的胶质瘤通常预后良好,但约19 - 44%因具有胶质母细胞瘤的基因特征而病程高度侵袭性。本回顾性研究的目的是利用灌注和扩散的生理磁共振成像参数来区分初诊时无强化的胶质瘤的分子特征。
纳入99例无强化的胶质瘤患者,这些患者有分子状态(包括1p/19q共缺失状态和异柠檬酸脱氢酶(IDH)突变)及术前磁共振成像(T2加权/液体衰减反转恢复序列、动态磁敏感加权成像和扩散加权成像)资料。使用ITK-SNAP半自动分割肿瘤,以获取相对脑血容量(rCBV)和表观扩散系数(ADC)的全肿瘤直方图。肿瘤被分为三种临床相关的分子特征:IDH突变(IDHmt)伴( = 40)或不伴( = 41)1p/19q共缺失,以及( = 18)IDH野生型(IDHwt)。使用SPSS进行方差分析、Kruskal-Wallis检验和卡方分析。
rCBV(均值、中位数、第75和85百分位数)和ADC(均值、中位数、第15和25百分位数)在分子特征间存在显著差异( <.01)。事后分析显示,与IDHmt 1p/19q完整的肿瘤相比,IDHwt和IDHmt 1p/19q共缺失的肿瘤rCBV显著更高:平均rCBV(均值,标准差)分别为1.46(0.59)和1.35(0.39),而IDHmt 1p/19q完整的肿瘤为1.08(0.31), <.05。此外,与IDHmt 1p/19q共缺失和IDHmt 1p/19q完整的肿瘤相比,IDHwt肿瘤的ADC显著更低:平均ADC(均值,标准差)为1.13(0.23),而IDHmt 1p/19q共缺失和IDHmt 1p/19q完整的肿瘤分别为1.27(0.15)和1.45(0.20), <.001)。
低ADC和高rCBV的组合,分别反映高细胞密度和高灌注,可将IDHwt与特别是IDHmt 1p/19q完整的胶质瘤区分开来。